Boule Diagnostics AB (publ)
SSE:BOUL.ST
9.36 (SEK) • At close February 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) SEK.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 558.6 | 571.329 | 548.088 | 463.344 | 400.458 | 498.916 | 424.4 | 427.793 | 400.735 | 331.407 | 306.687 | 276.804 | 275.301 | 246.155 | 229.421 | 175.391 | 168.694 |
| Cost of Revenue
| 306.2 | 321.615 | 320.182 | 264.709 | 223.273 | 272.705 | 234.682 | 225.107 | 206.064 | 181.58 | 170.242 | 155.34 | 151.795 | 138.116 | 127.207 | 102.656 | 104.13 |
| Gross Profit
| 252.4 | 249.714 | 227.906 | 198.635 | 177.185 | 226.211 | 189.718 | 202.686 | 194.671 | 149.827 | 136.445 | 121.464 | 123.506 | 108.039 | 102.214 | 72.735 | 64.563 |
| Gross Profit Ratio
| 0.452 | 0.437 | 0.416 | 0.429 | 0.442 | 0.453 | 0.447 | 0.474 | 0.486 | 0.452 | 0.445 | 0.439 | 0.449 | 0.439 | 0.446 | 0.415 | 0.383 |
| Reseach & Development Expenses
| 307.2 | 53.091 | 51.569 | 43.327 | 83.098 | 29.942 | 28.816 | 31.703 | 37.48 | 40.071 | 23.631 | 119.592 | 22.165 | 22.507 | 19.641 | 34.385 | 36.195 |
| General & Administrative Expenses
| 36.2 | 32.662 | 32.872 | 31.473 | 27.99 | 25.465 | 23.451 | 27.443 | 30.36 | 22.837 | 24.989 | 25.132 | 25.148 | 24.554 | 20.456 | 11.784 | 10.808 |
| Selling & Marketing Expenses
| 126.2 | 120.691 | 110.723 | 88.677 | 82.945 | 102.644 | 86.186 | 88.093 | 73.212 | 66.228 | 62.573 | 59.021 | 54.431 | 44.457 | 39.692 | 35.379 | 30.547 |
| SG&A
| 162.4 | 153.353 | 143.595 | 120.15 | 110.935 | 128.109 | 109.637 | 115.536 | 103.572 | 89.065 | 87.562 | 84.153 | 79.579 | 69.011 | 60.148 | 47.163 | 41.355 |
| Other Expenses
| 40.2 | 4 | -0.738 | -0.701 | -12.394 | -1.624 | 1.28 | 1.231 | 1.33 | 0.048 | 0.926 | 0.009 | 0.115 | -0.646 | 2.091 | 0.53 | -3.787 |
| Operating Expenses
| 509.8 | 210.4 | 194.426 | 162.776 | 181.639 | 156.427 | 137.173 | 142.034 | 144.547 | 129.193 | 105.084 | 203.688 | 101.796 | 90.872 | 81.88 | 82.078 | 73.762 |
| Operating Income
| -257.4 | 39.3 | 28.97 | 36.018 | -4.454 | 54.786 | 54.835 | 54.352 | 47.091 | 21.604 | 26.559 | -82.392 | 20.35 | 17.167 | 20.333 | -9.343 | -9.199 |
| Operating Income Ratio
| -0.461 | 0.069 | 0.053 | 0.078 | -0.011 | 0.11 | 0.129 | 0.127 | 0.118 | 0.065 | 0.087 | -0.298 | 0.074 | 0.07 | 0.089 | -0.053 | -0.055 |
| Total Other Income Expenses Net
| -11.1 | -9.2 | -8.121 | -7.25 | -43.094 | -19.451 | 2.19 | -3.335 | 2.568 | -1.203 | -1.629 | -1.831 | -1.476 | -0.204 | -1.658 | 13.434 | 3.65 |
| Income Before Tax
| -268.5 | 30.1 | 20.849 | 28.768 | -49.021 | 50.573 | 54.734 | 53.343 | 47.089 | 20.401 | 24.93 | -84.223 | 20.205 | 17.492 | 18.675 | -10.171 | -5.549 |
| Income Before Tax Ratio
| -0.481 | 0.053 | 0.038 | 0.062 | -0.122 | 0.101 | 0.129 | 0.125 | 0.118 | 0.062 | 0.081 | -0.304 | 0.073 | 0.071 | 0.081 | -0.058 | -0.033 |
| Income Tax Expense
| -45.2 | 5.123 | 8.121 | 5.496 | -1.056 | 13.026 | 13.703 | 16.104 | 11.056 | 5.049 | -5.335 | -14.098 | 9.246 | 7.405 | -0.216 | 0.377 | 5.397 |
| Net Income
| -223.3 | 24.977 | 12.728 | 23.272 | -47.965 | 37.548 | 41.031 | 37.239 | 36.033 | 15.352 | 30.265 | -70.125 | 10.959 | 11.711 | 18.891 | -10.548 | -5.549 |
| Net Income Ratio
| -0.4 | 0.044 | 0.023 | 0.05 | -0.12 | 0.075 | 0.097 | 0.087 | 0.09 | 0.046 | 0.099 | -0.253 | 0.04 | 0.048 | 0.082 | -0.06 | -0.033 |
| EPS
| -5.75 | 0.64 | 0.46 | 0.85 | -1.75 | 1.37 | 1.5 | 1.36 | 1.35 | 0.58 | 1.14 | -2.64 | 0.41 | 0.44 | 0.96 | -0.54 | -0.28 |
| EPS Diluted
| -5.75 | 0.64 | 0.45 | 0.83 | -1.75 | 1.37 | 1.5 | 1.36 | 1.32 | 0.57 | 1.14 | -2.64 | 0.41 | 0.44 | 0.96 | -0.54 | -0.28 |
| EBITDA
| -255.9 | 65.979 | 57.845 | 55.694 | 16.978 | 92.975 | 64.908 | 66.582 | 57.727 | 26.651 | 30.806 | -79.214 | 23.863 | 21.261 | 20.718 | 5.745 | -1.706 |
| EBITDA Ratio
| -0.458 | 0.115 | 0.106 | 0.12 | 0.042 | 0.186 | 0.153 | 0.156 | 0.144 | 0.08 | 0.1 | -0.286 | 0.087 | 0.086 | 0.09 | 0.033 | -0.01 |